Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases

Harpreet Wasan, Andrew Kennedy*, Douglas Coldwell, Bruno Sangro, Riad Salem

*Corresponding author for this work

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Clinical decisions regarding the treatment of metastatic colorectal cancer require consideration of current and evolving modalities to best achieve prolonged patient survival. Clinical trials have established that for first-line treatment of patients with or without extrahepatic metastases, radioembolization augments the response produced by chemotherapy in patients with unresectable liver metastases. This includes progression-free and overall survivals that compare favorably with phase II to III data of current chemotherapy regimens. The increased response rate with radioembolization and first-line chemotherapy may improve the likelihood for potentially curative hepatic lesion resection or ablation. Application of an innovative multidisciplinary treatment approach that integrates radioembolization and local ablative therapy may enable the benefits of curative hepatic resection to be extended to a broader group of patients.

Original languageEnglish (US)
Pages (from-to)293-301
Number of pages9
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Neoplasm Metastasis
Drug Therapy
Liver
Therapeutics
Disease-Free Survival
Colorectal Neoplasms
Clinical Trials
Survival

Keywords

  • SIRT
  • Yttrium-90
  • colon
  • hepatic
  • rectum

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{ef267d517b35471e903e249f89ed1a8e,
title = "Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases",
abstract = "Clinical decisions regarding the treatment of metastatic colorectal cancer require consideration of current and evolving modalities to best achieve prolonged patient survival. Clinical trials have established that for first-line treatment of patients with or without extrahepatic metastases, radioembolization augments the response produced by chemotherapy in patients with unresectable liver metastases. This includes progression-free and overall survivals that compare favorably with phase II to III data of current chemotherapy regimens. The increased response rate with radioembolization and first-line chemotherapy may improve the likelihood for potentially curative hepatic lesion resection or ablation. Application of an innovative multidisciplinary treatment approach that integrates radioembolization and local ablative therapy may enable the benefits of curative hepatic resection to be extended to a broader group of patients.",
keywords = "SIRT, Yttrium-90, colon, hepatic, rectum",
author = "Harpreet Wasan and Andrew Kennedy and Douglas Coldwell and Bruno Sangro and Riad Salem",
year = "2012",
month = "6",
day = "1",
doi = "10.1097/COC.0b013e3182005747",
language = "English (US)",
volume = "35",
pages = "293--301",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases. / Wasan, Harpreet; Kennedy, Andrew; Coldwell, Douglas; Sangro, Bruno; Salem, Riad.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 3, 01.06.2012, p. 293-301.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Integrating radioembolization with chemotherapy in the treatment paradigm for unresectable colorectal liver metastases

AU - Wasan, Harpreet

AU - Kennedy, Andrew

AU - Coldwell, Douglas

AU - Sangro, Bruno

AU - Salem, Riad

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Clinical decisions regarding the treatment of metastatic colorectal cancer require consideration of current and evolving modalities to best achieve prolonged patient survival. Clinical trials have established that for first-line treatment of patients with or without extrahepatic metastases, radioembolization augments the response produced by chemotherapy in patients with unresectable liver metastases. This includes progression-free and overall survivals that compare favorably with phase II to III data of current chemotherapy regimens. The increased response rate with radioembolization and first-line chemotherapy may improve the likelihood for potentially curative hepatic lesion resection or ablation. Application of an innovative multidisciplinary treatment approach that integrates radioembolization and local ablative therapy may enable the benefits of curative hepatic resection to be extended to a broader group of patients.

AB - Clinical decisions regarding the treatment of metastatic colorectal cancer require consideration of current and evolving modalities to best achieve prolonged patient survival. Clinical trials have established that for first-line treatment of patients with or without extrahepatic metastases, radioembolization augments the response produced by chemotherapy in patients with unresectable liver metastases. This includes progression-free and overall survivals that compare favorably with phase II to III data of current chemotherapy regimens. The increased response rate with radioembolization and first-line chemotherapy may improve the likelihood for potentially curative hepatic lesion resection or ablation. Application of an innovative multidisciplinary treatment approach that integrates radioembolization and local ablative therapy may enable the benefits of curative hepatic resection to be extended to a broader group of patients.

KW - SIRT

KW - Yttrium-90

KW - colon

KW - hepatic

KW - rectum

UR - http://www.scopus.com/inward/record.url?scp=84861528516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861528516&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182005747

DO - 10.1097/COC.0b013e3182005747

M3 - Review article

C2 - 21278562

AN - SCOPUS:84861528516

VL - 35

SP - 293

EP - 301

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -